NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Sees Large Drop in Short Interest

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) saw a significant drop in short interest in December. As of December 31st, there was short interest totaling 62,431 shares, a drop of 40.8% from the December 15th total of 105,433 shares. Based on an average daily trading volume, of 305,911 shares, the short-interest ratio is presently 0.2 days. Approximately 0.1% of the shares of the stock are sold short. Approximately 0.1% of the shares of the stock are sold short. Based on an average daily trading volume, of 305,911 shares, the short-interest ratio is presently 0.2 days.

NeuroOne Medical Technologies Price Performance

Shares of NMTC stock traded up $0.00 during trading hours on Friday, reaching $0.90. The stock had a trading volume of 242,637 shares, compared to its average volume of 344,518. NeuroOne Medical Technologies has a twelve month low of $0.40 and a twelve month high of $1.39. The firm has a market capitalization of $45.51 million, a PE ratio of -11.29 and a beta of 0.70. The firm has a 50-day simple moving average of $0.74 and a 200-day simple moving average of $0.79.

NeuroOne Medical Technologies (NASDAQ:NMTC) last posted its quarterly earnings data on Tuesday, December 16th. The company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.08. The business had revenue of $2.74 million during the quarter, compared to analysts’ expectations of $2.47 million. NeuroOne Medical Technologies had a negative net margin of 29.81% and a negative return on equity of 74.69%. During the same period last year, the firm posted ($0.46) earnings per share.

Institutional Trading of NeuroOne Medical Technologies

Institutional investors and hedge funds have recently bought and sold shares of the stock. Goldman Sachs Group Inc. purchased a new stake in shares of NeuroOne Medical Technologies during the 1st quarter worth about $84,000. Sio Capital Management LLC acquired a new position in NeuroOne Medical Technologies in the second quarter worth approximately $2,390,000. Warberg Asset Management LLC acquired a new position in NeuroOne Medical Technologies in the second quarter worth approximately $27,000. Vanguard Group Inc. raised its position in NeuroOne Medical Technologies by 31.2% during the third quarter. Vanguard Group Inc. now owns 1,578,237 shares of the company’s stock valued at $1,403,000 after acquiring an additional 375,639 shares in the last quarter. Finally, Virtu Financial LLC acquired a new stake in NeuroOne Medical Technologies in the third quarter valued at approximately $88,000. Institutional investors and hedge funds own 16.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NeuroOne Medical Technologies in a research report on Wednesday, October 8th. Zacks Research raised shares of NeuroOne Medical Technologies from a “hold” rating to a “strong-buy” rating in a research report on Monday, January 5th. Finally, Wall Street Zen raised shares of NeuroOne Medical Technologies to a “hold” rating in a research report on Friday, October 3rd. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $2.23.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.